Zhejiang Ausun Pharmaceutical 과거 수익 실적
과거 기준 확인 2/6
Zhejiang Ausun Pharmaceutical has been growing earnings at an average annual rate of 30.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 21% per year. Zhejiang Ausun Pharmaceutical's return on equity is 11.2%, and it has net margins of 30.8%.
주요 정보
30.2%
수익 성장률
28.4%
EPS 성장률
Pharmaceuticals 산업 성장 | 10.9% |
매출 성장률 | 21.0% |
자기자본 수익률 | 11.2% |
순이익 | 30.8% |
최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise
Oct 08Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet
Jul 31Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock's 27% Jump Looks Justified
Mar 06수익 및 비용 분석
Zhejiang Ausun Pharmaceutical 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 24 | 835 | 258 | 112 | 68 |
30 Jun 24 | 840 | 274 | 108 | 71 |
31 Mar 24 | 800 | 250 | 126 | 77 |
31 Dec 23 | 817 | 254 | 118 | 78 |
30 Sep 23 | 858 | 284 | 125 | 88 |
30 Jun 23 | 852 | 273 | 142 | 86 |
31 Mar 23 | 822 | 258 | 122 | 78 |
31 Dec 22 | 765 | 235 | 118 | 67 |
30 Sep 22 | 718 | 213 | 110 | 72 |
30 Jun 22 | 665 | 186 | 94 | 64 |
31 Mar 22 | 631 | 173 | 84 | 64 |
31 Dec 21 | 570 | 146 | 83 | 69 |
30 Sep 21 | 537 | 131 | 76 | 57 |
30 Jun 21 | 485 | 117 | 66 | 50 |
31 Mar 21 | 474 | 110 | 69 | 52 |
31 Dec 20 | 409 | 87 | 63 | 51 |
30 Sep 20 | 406 | 72 | 71 | 61 |
30 Jun 20 | 389 | 78 | 69 | 67 |
31 Mar 20 | 329 | 70 | 60 | 55 |
31 Dec 19 | 308 | 56 | 57 | 48 |
30 Sep 19 | 293 | 62 | 49 | 41 |
30 Jun 19 | 257 | 51 | 50 | 36 |
31 Mar 19 | 252 | 50 | 48 | 37 |
31 Dec 18 | 244 | 44 | 45 | 34 |
30 Sep 18 | 255 | 54 | 48 | 34 |
30 Jun 18 | 266 | 52 | 32 | 44 |
31 Mar 18 | 251 | 43 | 38 | 35 |
31 Dec 17 | 240 | 53 | 41 | 30 |
30 Sep 17 | 217 | 55 | 38 | 19 |
30 Jun 17 | 216 | 62 | 53 | 0 |
31 Mar 17 | 197 | 58 | 48 | 0 |
31 Dec 16 | 199 | 57 | 48 | 0 |
31 Mar 16 | 259 | 62 | 65 | 0 |
31 Dec 15 | 263 | 61 | 65 | 0 |
31 Dec 14 | 201 | 22 | 74 | 0 |
31 Dec 13 | 121 | 16 | 31 | 0 |
양질의 수익: 603229 has high quality earnings.
이익 마진 증가: 603229's current net profit margins (30.8%) are lower than last year (33%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 603229's earnings have grown significantly by 30.2% per year over the past 5 years.
성장 가속화: 603229's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
수익 대 산업: 603229 had negative earnings growth (-9.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
자기자본 수익률
높은 ROE: 603229's Return on Equity (11.2%) is considered low.